ClinicalTrials.gg
RecruitingNCT06884189aPPPleUpdated Mar 19, 2025

Application of Plant Protection Products (PPP) in Apple Orchards

An observational study in Dermal Exposure, Inhalative Exposure and Metabolites in Urine, sponsored by German Federal Institute for Risk Assessment. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by German Federal Institute for Risk Assessment · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the aPPPle pilot study is to test feasibility and generate first results in preparation for a main study. The aPPPle study will investigate the exposure of operators, workers and residents to plant protection products (PPP) and potential physiological effects on blood biomarkers. The target plants are apple crops, as application occurs at higher altitudes and therefore higher drift/exposure is expected compared to ground-level application. The substances to be investigated are acetamiprid (an insecticide) and dithianon and dodine (two fungicides).

02

Conditions studied

  • Dermal Exposure
  • Inhalative Exposure
  • Metabolites in Urine
  • Effekt Biomarker in Blood

Keywords

  • exposure study
  • plant protection products
  • human biomonitoring
  • effect biomarker
03

In context

Lead sponsor

German Federal Institute for Risk Assessment is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Users, residents and workers:

people from "Altes Land", a large apple-growing region in northern Germany

Control: live at least 10 km and max. 150 km away from agricultural apple orchards

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • belonging to one of the defined study groups
  • over 18 years of age at the time of recruitment
  • person can understand the language and content of the study requirements
  • person is capable of consenting to participate in the study and has given written consent to participate in the aPPPle study
  • person has health insurance

Exclusion criteria

Exclusion Criteria for residents and control:

person has direct professional contact with the tested substances acetamiprid, dithianon or dodine

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (estimated)
Patient registry
No

Groups and cohorts

  • Operators

    People who apply plant protection products to apple crops.

  • Workers

    People who do manual work in apple cultivation, like pruning or harvesting.

  • Residents

    People whose place of residence is adjacent to the orchard under investigation.

  • Control

    People whose place of residence is at least 10 km away from agricultural apple orchards and a maximum of 150 km away from the apple orchard under investigation.

06

What researchers measure

Primary outcomes

  1. Concentration of plant protection substances/metabolites in different matrices

    The concentrations of the investigated substances/their metabolites will be analysed in urine, patches (to assess dermal exposure of the body), hand wipes (to assess dermal exposure of the hands), filters of an personal air sampler (to assess inhalation exposure), hair samples and gras samples

    Time frame: Operators: during the observed work with PPP and for urine up to 48 hours after; resident: during the observed application and for urine up to 48 hours after; workers: during work in the orchards and for urine up to 48 hours a; control: at one time point

  2. Effect biomarkers in blood and metabolome in plasma

    Defined effect biomarkers in blood as well as the metabolome in plasma will be analysed before and after application of plant protection products to observe possible early physiological changes. The following effect biomarkers in the blood will be measured: c-reactive protein, fasting glucose, HbA1c, cortisol, oxidized LDL, complete blood count, thyrotropin (TSH), free T3 (fT3), free T4 (fT4), gamma GT, GOT (ASAT), GPT (ALAT), bilirubin, cystatin C, urea

    Time frame: enrollment until 7 days after application/work in the apple orchards; for people from the control group at one time point

07

Study locations

1 of 1 sites recruiting
  • Federal Institute for Risk Assessment
    Berlin, 10589, Germany
    Recruiting
    • Prof. Dr. Cornelia Weikert · Contactcornelia.weikert@bfr.bund.de · +49 301841255000
    • Prof. Dr. Cornelia Weikert · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2025
First posted
Mar 19, 2025
StartActual
Mar 11, 2025
Primary completionEst.
Dec 20, 2025
CompletionEst.
Dec 20, 2025
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06884189
Lead sponsor
German Federal Institute for Risk Assessment
Collaborators
Federal Ministry of Food and Agriculture, ESTEBURG Obstbauzentrum Jork Kompetenzzentrum für den norddeutschen Obstbau
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Mar 11, 2025
Primary completion
Dec 20, 2025 (estimated)
Completion
Dec 20, 2025 (estimated)
Last update
Mar 19, 2025

Study contacts

Prof. Dr. Cornelia Weikert
Contact
cornelia.weikert@bfr.bund.de
+49 301841255000
Dr. Anna Lechner
Contact
anna.lechner@bfr.bund.de
+49 301841255015

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

German Federal Institute for Risk Assessment

Start the discussion